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Differential gene expression analysis using databases followed by overall 
survival (OS) analysis is currently used to identify different oncogenes 
and tumour suppressor genes. The present study identified coiled coiled 
domain containing protein 69 (CCDC69) as a tumour suppressor gene in 
breast cancer by differential gene expression analysis using TCGA data-
set for breast adenocarcinoma (BRCA) followed by OS and relapse free 
survival (RFS) analysis using Kaplan Meier (KM) plotter tool. CCDC69 
was observed to be down regulated in tumour of breast cancer patients 
in BRCA. Following OS analysis for different breast cancer sub-types, 
low expression of CCDC69 has been observed to be associated with poor 
survival in HER2+ breast cancer only. CCDC69 was also found to be 
down regulated in different HER2+ breast cancer cells by analysing Gene 
Expression Omnibus (GEO) database. Additionally, CCDC69 was found 
to be under expressed in single cell HER2 positive population, which is 
evident from the single cell expression ATLAS database. Furthermore, 
CCDC69 has been observed to be lowly expressed with overexpression 
of HER2 in breast cancer by co-expression study. The possible mecha-
nism of CCDC69 down regulation in HER2+ breast cancer was resolved 
using P-SCAN tool. P-SCAN analysis suggested a group of transcription 
factors (TFs) among which androgen receptor (AR) has been selected as 
the probable TF that could play a role in CCDC69 down regulation in 
HER2+ breast cancer. Moreover, overexpression of AR has been observed 
in BRCA and HER2+ single cell population. AR has also been observed 
to be co-expressed positively with HER2, but negatively with CCDC69 
in breast cancer. Down regulation of CCDC69 can be predicted to stabi-
lize microtubule formation following stimulation of cell growth and cell 
migration leading to HER2+ breast cancer progression and metastasis. 
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1. Introduction
Breast cancer is a rapidly growing and the most pre-dominant disease of cancer mediated morbidity and mortality in women all over the world. The possi-
bility of recurrence of breast cancer depends on the tumour 
size, grade, nodal status, tumour subtype and especially 
mode of therapy [1]. The presence of hormonal receptors 
“estrogen receptor (ER) and progesterone receptor (PR)” 
and HER-2 “human epidermal growth factor receptor 2” re-
ceptor in the tumour cells have been selected as one of the 
important factors for the diagnosis of breast cancer. Based 
on the expression of these receptors, breast cancer has been 
divided into different sub-types: luminal A, luminal B, tri-
ple negative and HER2 positive [2]. Over the past decade, 
advancement with cancer research using different databas-
es, high throughput technologies, clinical trial allowed the 
discovery of new drugs for treatment of breast cancer. Bet-
ter understanding of phenotype and heterogeneity of breast 
cancer has opened the possibility for the development of 
more effective and individualized approach to treatment. 
The most common treatments that currently available are 
surgery, radiation therapy and chemotherapy. Surgery and 
radiation therapy are the most common treatment options 
for primary tumours and large metastases, while chemo-
therapy is the best treatment option for metastatic tumours. 
Traditional anticancer chemotherapeutic drugs inhibit can-
cer cell division and DNA replication leading to prevention 
of breast cancer. However, they do not seem to be appro-
priate in all types of cancer. Regarding the background and 
disadvantage of chemotherapy, complementary treatment 
modalities are being widely explored in recent years. For 
example, molecular therapy, anti-angiogenesis therapy, 
immunotherapy, apoptosis regulation, signal-transduction 
therapy, targeted radionuclide therapy and nucleic acid 
based therapies have attracted attention from the health care 
system [3]. Therefore, finding new therapeutic targets such 
as oncogenes, tumour suppressor genes, signalling mole-
cules are the recent trends of research for targeted therapy 
to combat cancer. Targeted therapy exerts its anticancer ef-
fects through multiple mechanisms, including arrest of cell 
growth, induction of apoptosis, and suppression of spread-
ing of tumour (a.k.a tumour metastasis) as well as immune 
function regulation and multidrug resistance reversal.
Differential gene expression analysis using different da-
tabases followed by OS is important in the cancer research. 
This can help in identifying different oncogenes and tumour 
suppressor genes. The aim of our study was to identify a 
novel tumour suppressor gene in breast cancer. Herein, we 
have identified CCDC69 as a tumour suppressor gene in 
breast cancer by differential gene expression analysis using 
TCGA dataset for BRCA followed by OS and RFS analysis 
using KM plot and CCDC69 has been found to be down 
regulated in HER2+ breast cancer. Transcription factor, AR 
was predicted by our in silico study as the key regulator for 
the down regulation of CCDC69 in HER2+ breast cancer.
2. Methods and Tools
2.1 Differential Gene Expression Analysis Using 
Gene Expression Profiling Interactive Analysis 
(GEPIA) Tool
GEPIA allows users to input custom statistical methods 
and thresholds for TCGA dataset to dynamically obtain 
differentially expressed genes. The differential gene ex-
pression analysis for the present study has been done 
using GEPIA online server tool. Details of the method are 
described in the GEPIA website [4].
2.1 Overall Survival (OS) Analysis Using Kaplan 
Meier Plotter
The Kaplan Meier plotter is capable to assess the effect 
of 54k genes on survival in 21 cancer types. The largest 
datasets include breast (n=6,234), ovarian (n=2,190), lung 
(n=3,452), and gastric (n=1,440) cancer. Details of the 
method are described in the KM plotter website [5].
2.3 MTCI Breast Cancer Overall Survival Tool
Molecular Therapeutics for Cancer, Ireland (MTCI) is a 
Science Foundation Ireland-funded strategic research cluster 
which aims to discover and develop new anti-cancer drugs. 
Details of the method are described in the MTCI website.
2.4 Single Cell Expression Atlas - EMBL-EBI
EMBL-EBI Single Cell Expression Atlas, an open public 
repository of single cell gene expression data. Details of 
the method are described in the Single Cell Expression 
Atlas - EMBL-EBI website.
2.5 Statistical Analysis
Statistical analyses were followed according to the anal-
ysis has been done in different tools that are used in the 
present study. Details of the method are available in the 
website of the tools. 
3. Results and Discussion
3.1 Differential Gene Expression Analysis Identi-
fies CCDC69 as a Tumour Suppressor Gene
 To find out a novel tumour suppressor gene in breast 
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cancer, we have first undertaken differential gene expres-
sion analysis (log2 fold change cut off and p value were 
considered ≤-2 and ≤.001 respectively) for BRCA in 
TCGA dataset using GEPIA (Gene Expression Profiling 
Interactive Analysis) tool followed by OS and RFS anal-
ysis using KM-Plotter. We have selected CCDC69, which 
may act as a tumour suppressor in breast cancer following 
literature study since we did not find significant number 
of publications that suggests CCDC69 role as tumour 
suppressor in breast cancer. CCDC69 has been observed 
to be down regulated in different types of cancer includ-
ing breast in TCGA dataset (Figure 1 A-C).  Especially, 
CCDC69 mRNA was under expressed in breast tumour 
sample (~6 fold compared to normal) in BRCA in TCGA 
dataset (Figure 1D). OS analysis and RFS analysis for 
breast cancer using KM-Plot suggested low expression of 
CCDC69 is associated with poor survival with a p value 
of 8.2e-07 and 7.8e-16, respectively, which predicts that 
CCDC69 may strongly acts as a tumour suppressor gene 
in breast cancer (Figure 2A). 
Figure 1. CCDC69 expression in different cancers
3.2 OS Analysis for Different Breast Cancer Sub-
types Predicts that CCDC69 may Play Role only 
in HER2+ Breast Cancer
Although low expression of CCDC69 expression was 
found to be associated with poor survival in breast cancer, 
it is important to know in which breast cancer sub-type 
CCDC69 may play role as a tumour suppressor. To this 
end, OS analysis has been performed for different breast 
cancer subtypes using MTCI breast cancer survival analy-
sis tool. CCDC69 expression was not found to be associ-
ated with poor survival in LUMA, LUMB and triple nega-
tive breast cancer subtypes (p values are 0.216, 0.656 and 
0.677 respectively); however, low expression of CCDC69 
was found to be associated with poor survival in HER2+ 
breast cancer population with a p value of 0.05 (Figure 
2B). Next to determine whether CCDC69 is under ex-
pressed in HER2+ breast cancer cell lines, we used GEO 
dataset to see CCDC69 mRNA expression in different 
breast cancer cells. Our study revealed that CCDC69 is 
down regulated in different HER2+ positive breast cancer 
cell lines (Figure 3A). We have also checked CCDC69 ex-
pression in single cell population isolated from breast can-
cer patients using single cell expression ATLAS database. 
Interestingly, CCDC69 was found very lowly expressed in 
HER2+ single cell population (Figure 3B). Additionally, 
we determined whether CCDC69 is co-expressed with 
HER2 in breast cancer by co-expression analysis and the 
Figure 2. A) Overall survival analysis plot of CCDC69 
in breast cancer; B) Overall survival analysis plot of 
CCDC69 in different breast cancer sub-types
DOI: https://doi.org/10.30564/jhp.v1i2.1578
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study indicated that CCDC69 is co-expressed negatively 
with HER2 (Figure 3C). Overall, the above observations 
strongly support CCDC69 down regulation in HER2+ 
breast cancer cells.   
Figure 3. CCDC69 expression in different breast cancer 
cell lines and single cell population
3.3 Role of CCDC69 Co-expressed Genes in 
Breast Cancer
Gene co-expression analysis is used to identify the func-
tion of an unknown gene in biological processes to priori-
tize the role of the candidate gene in diseases and to deter-
mine transcriptional regulatory programmes [6]. To gain an 
insight in the function of CCDC69 in biological process 
or in disease regulation, we did co-expression study with 
the use of genevestigator tool. Co-expression analysis re-
vealed 25 genes which are further analysed for their role 
in breast cancer using TCGA dataset for BRCA (Figure 
4A). Unfortunately, expression of not a single gene among 
the 25 genes was found to be changed significantly in tu-
mour tissue compared to normal tissue in TCGA dataset 
(Figure 4B). Therefore, it may be concluded that CCDC69 
is down regulated exclusively in BRCA in comparison to 
its co-expressed genes. Next to determine the function of 
CCDC69 or its role in signalling pathways, we have used 
gene analytics tool. No signalling pathways, however, has 
been observed where CCDC69 appears to be involved and 
could play a significant role leading to breast cancer pro-
gression. Nevertheless, literature study indicated a role of 
CCDC69 in the activation of p14ARF/MDM2/p53 signal-
ling pathway in ovarian cancer [7]. Thus, in vitro study that 
shows a functional role of CCDC69 in breast cancer will 
be required in future.
Figure 4. CCDC69 co expressed genes and their role in 
breast cancer
3.4 AR may be Involved in the down Regulation 
of CCDC69 in HER2+ Breast Cancer
Since CCDC69 was found to be down regulated in 
HER2+ breast cancer and as OS analysis strongly supports 
its role as a tumour suppressor; therefore it appears essen-
tial to know the mechanism by which CCDC69 is down 
regulated. To this end, P-SCAN analysis was performed 
to identify possible transcription repressors that may bind 
to the CCDC69 promoter region leading to suppression of 
CCDC69 mRNA transcription. P-SCAN analysis identi-
fied top 15 transcription factors with significant p value, of 
which androgen receptor (AR) was selected as the prob-
able regulator of CCDC69 (Figure 5A). AR was selected 
to cause CCDC69 mRNA down regulation in HER2+ 
breast cancer because AR was found to be co-expressed 
with HER2 positively; however, negatively with CCDC69 
by co-expression analysis (Figure 5B & C). Additionally, 
AR was found to be overexpressed in the tumour of breast 
cancer patients TCGA dataset for BRCA (Figure 5D). 
Interestingly, gene expression analysis for AR in single 
cell dataset suggests that AR is overexpressed in HER2+ 
breast cancer subtype (Figure 5E).
Figure 5. Mechanism of CCDC69 down regulation in 
HER2+ breast cancer
DOI: https://doi.org/10.30564/jhp.v1i2.1578
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Transcription factors can act both as a transcriptional 
activator or repressor depending on the cell system. AR 
has been indicated to act as a transcriptional repressor in 
a recently published article [8]. Therefore, it is suggested 
that overexpressed AR may bind to the CCDC69 promot-
er leading to the transcriptional repression of CCDC69 in 
HER2+ breast cancer.
4. Conclusion and Future Prospects
The present in silico study identifies CCDC69 as a novel 
tumour suppressor gene in HER2+ breast cancer. The 
probable mechanism for CCDC69 down regulation in 
HER2+ breast cancer was resolved and AR is suggested 
as the predominant transcriptional repressor for the under 
expression of CCDC69 mRNA in HER2+ breast cancer. 
The present study will open the possibility of a wet lab 
work to verify the role of CCDC69 as a tumour suppres-
sor in HER2+ breast cancer. The present study also sug-
gests that AR can be a therapeutic target in HER2+ breast 
cancer and its inhibition can be considered as a therapeu-
tic strategy in HER2+ breast cancer treatment. Functional 
study of CCDC69 and identifying the mechanism by 
which CCDC69 play a role in HER2+ breast cancer are 
also seem to be promising for future study. Recent study 
demonstrated that CCDC69 can destabilize microtubules 
[9]. Knockdown of CCDC69 by RNAi leads to the forma-
tion of aberrant central spindles and interferes with the 
localization of midzone components such as aurora B, 
PRC1, MgcRacGAP, and Plk1 leading to stabilization of 
microtubules [9]. It is well known that microtubules sta-
bilization induces cell proliferation and migration [10,11]. 
Conceivably, it can be speculated that down regulation of 
CCDC69 may stabilize microtubule formation and sub-
sequently stimulates cell growth and migration leading to 
breast cancer progression and metastasis. Hence, overex-
pression of CCDC69 in HER2+ breast cancer may be a 
therapeutic strategy for the treatment in future.
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